Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B R Sellman

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Molecular Microbiology|August 1, 1997
The propeptide of Clostridium septicum alpha toxin functions as an intramolecular chaperone and is a potent inhibitor of alpha toxin-dependent cytolysisB R Sellman, R K Tweten
Science (New York, N.Y.)|April 28, 2001
Dominant-negative mutants of a toxin subunit: an approach to therapy of anthraxB R Sellman, M Mourez, R J Collier
The Journal of Biological Chemistry|December 13, 2000
Point mutations in anthrax protective antigen that block translocationB R Sellman, S Nassi, R J Collier
Molecular Microbiology|February 1, 1997
Generation of a membrane-bound, oligomerized pre-pore complex is necessary for pore formation by Clostridium septicum alpha toxinB R Sellman, B L Kagan, R K Tweten
Molecular Microbiology|February 27, 1999
Expression and properties of an aerolysin--Clostridium septicum alpha toxin hybrid proteinD B Diep, K L Nelson, T S Lawrence, et al.
The British Journal of Dermatology|October 26, 2016
The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapiesL Hepburn, D J Hijnen, B R Sellman, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2018
Alanine Scanning Mutagenesis of the MEDI4893 (Suvratoxumab) Epitope Reduces Alpha Toxin Lytic Activity <i>In Vitro</i> and Staphylococcus aureus Fitness in Infection ModelsC Tkaczyk, E Semenova, Y Y Shi, et al.
Nature Biotechnology|October 3, 2001
Designing a polyvalent inhibitor of anthrax toxinM Mourez, R S Kane, J Mogridge, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2015
MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia ModelL Hua, T S Cohen, Y Shi, et al.
Immuno-Oncology Technology|June 27, 2022
Intervention strategies for microbial therapeutics in cancer immunotherapyV Gopalakrishnan, B Weiner, C B Ford, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Molecular Microbiology|August 1, 1997
The propeptide of Clostridium septicum alpha toxin functions as an intramolecular chaperone and is a potent inhibitor of alpha toxin-dependent cytolysisB R Sellman, R K Tweten
Science (New York, N.Y.)|April 28, 2001
Dominant-negative mutants of a toxin subunit: an approach to therapy of anthraxB R Sellman, M Mourez, R J Collier
The Journal of Biological Chemistry|December 13, 2000
Point mutations in anthrax protective antigen that block translocationB R Sellman, S Nassi, R J Collier
Molecular Microbiology|February 1, 1997
Generation of a membrane-bound, oligomerized pre-pore complex is necessary for pore formation by Clostridium septicum alpha toxinB R Sellman, B L Kagan, R K Tweten
Molecular Microbiology|February 27, 1999
Expression and properties of an aerolysin--Clostridium septicum alpha toxin hybrid proteinD B Diep, K L Nelson, T S Lawrence, et al.
The British Journal of Dermatology|October 26, 2016
The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapiesL Hepburn, D J Hijnen, B R Sellman, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2018
Alanine Scanning Mutagenesis of the MEDI4893 (Suvratoxumab) Epitope Reduces Alpha Toxin Lytic Activity <i>In Vitro</i> and Staphylococcus aureus Fitness in Infection ModelsC Tkaczyk, E Semenova, Y Y Shi, et al.
Nature Biotechnology|October 3, 2001
Designing a polyvalent inhibitor of anthrax toxinM Mourez, R S Kane, J Mogridge, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2015
MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia ModelL Hua, T S Cohen, Y Shi, et al.
Immuno-Oncology Technology|June 27, 2022
Intervention strategies for microbial therapeutics in cancer immunotherapyV Gopalakrishnan, B Weiner, C B Ford, et al.
Pageof 2